Biosafety Regulations — Current Affairs 2026
Current Affairs Connections
GEAC Approves Environmental Release of GM Mustard (DMH-11) for Seed Production, Commercial Cultivation Awaits Final Nod
October 25, 2022 (GEAC approval), ongoing litigation in 2024In a significant development, the Genetic Engineering Appraisal Committee (GEAC) under the MoEFCC, India's apex biosafety regulator, approved the environmental release of GM Mustard hybrid DMH-11 for seed production and testing. This marks the first time a GM food crop has received such an advanced stage of approval in India since Bt Brinjal in 2010 (which was later put under an indefinite moratorium). The approval is for environmental release for seed production and testing, not for commercial cultivation directly. However, the decision has been challenged in the Supreme Court, leading to ongoing legal battles and public debates. This event highlights the persistent regulatory and public acceptance challenges for GM crops in India, despite scientific clearances. The GEAC's decision was based on extensive biosafety data, but critics continue to raise concerns about potential impacts on biodiversity, honeybees, and the socio-economic implications for farmers.
UPSC Angle: Crucial for understanding the practical functioning of GEAC, the multi-stakeholder debates surrounding GM crops, the role of judiciary in environmental matters, and the balance between food security, agricultural innovation, and biosafety concerns. Aspirants should track the Supreme Court's final decision and its implications for India's agricultural biotechnology policy.
India Releases Guidelines for Research and Development of Gene-Edited Organisms, Exempting Certain Categories from Stringent GMO Rules
March 30, 2022 (MoEFCC Notification), DBT Guidelines updated 2024The Ministry of Environment, Forest and Climate Change (MoEFCC) issued a notification in March 2022, exempting certain categories of gene-edited organisms (specifically SDN-1 and SDN-2, which do not involve foreign DNA insertion) from the purview of the Biosafety Rules, 1989. This move aims to streamline research and development in gene editing technologies like CRISPR/Cas9, recognizing that some targeted edits are analogous to conventional breeding. Subsequently, the Department of Biotechnology (DBT) has been working on detailed guidelines for these exempted categories, and for SDN-3 (which involves foreign DNA) and other complex gene-edited products, which remain under the existing stringent regulatory framework. This regulatory update is a forward-looking step to adapt India's biosafety framework to rapidly advancing biotechnologies, fostering innovation while maintaining safety oversight. It reflects a global trend towards risk-proportionate regulation for gene-edited products.
UPSC Angle: Important for understanding how India's regulatory framework is adapting to emerging technologies. It highlights the distinction between different types of gene editing, the rationale behind differential regulation, and the potential impact on agricultural and medical biotechnology research in India. This is a key area for Prelims and Mains questions on science and technology policy and regulatory governance.